BUDGET IMPACT ANALYSIS OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB AS A TREATMENT FOR PREVIOUSLY UNTREATED LLC PATIENTS IN SPAIN

被引：0
|
作者：
Moreno, Martinez Estela [1 ]
De la Serna, Torroba Javier [2 ]
Escudero, Vilaplana Vicente [3 ]
Hernandez, Rivas Jose Angel [4 ]
Sanchez, Cuervo Marina [5 ]
Sanchez, Hernandez Raquel [6 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp 12 Octubre, Madrid, Spain
[3] Hosp Univ Gregorio Maranon, Madrid, Spain
[4] Hosp Infanta Leonor, Madrid, Spain
[5] Hosp Ramon & Cajal, Madrid, Spain
[6] Abbvie Spain SLU, Madrid, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-128
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [31] Total cost of care with 12 months fixed duration of venetoclax plus obinutuzumab in previously-untreated chronic lymphocytic leukemia (CLL) patients
    Cho, Sang Kyu
    Manzoor, Beenish
    Sail, Kavita
    Ravelo, Arliene
    Shapouri, Sheila
    Sharmokh, Simon
    Kapustyan, Tatyana
    Johnson, Scott
    Parise, Helene
    Virabhak, Suchin
    Davids, Matthew
    LEUKEMIA & LYMPHOMA, 2020, 61 : 57 - 57
  • [32] COSTS PER RESPONDER WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE IN UNFIT PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA IN CHINA
    Xu, H.
    Zhao, X.
    Mo, X.
    Zhao, J.
    Liu, J.
    Yang, Y.
    VALUE IN HEALTH, 2024, 27 (06) : S152 - S152
  • [33] BUDGET IMPACT ANALYSIS OF IVOSIDENIB IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF PREVIOUSLY UNTREATED MIDH1 POSITIVE ACUTE MYELOID LEUKAEMIA (AML) PATIENTS, INELIGIBLE FOR INTENSIVE INDUCTION CHEMOTHERAPY IN GREECE
    Koulentaki, M.
    Ravanidis, S.
    Vellopoulou, K.
    Karathanou, F.
    Chotzagiannoglou, V
    Beletsi, A.
    Kourlaba, G.
    VALUE IN HEALTH, 2024, 27 (12) : S109 - S109
  • [34] MAJIC: a phase III trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Ryan, Christine E.
    Davids, Matthew S.
    Hermann, Richard
    Shahkarami, Mina
    Biondo, Juliana
    Abhyankar, Sarang
    Alhasani, Hasan
    Sharman, Jeff P.
    Mato, Anthony R.
    Roeker, Lindsey E.
    FUTURE ONCOLOGY, 2022, 18 (33) : 3689 - 3699
  • [35] BUDGET IMPACT ANALYSIS OF OBINUTUZUMAB AND IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN RUSSIA
    Derkach, E., V
    Rebrova, O. Y.
    Fedyaeva, V. K.
    VALUE IN HEALTH, 2016, 19 (07) : A582 - A582
  • [36] Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
    Angel Calleja, Miguel
    Albanell, Joan
    Aranda, Enrique
    Garcia-Foncillas, Jesus
    Feliu, Anna
    Rivera, Fernando
    Oyaguez, Itziar
    Salinas-Ortega, Laura
    Soto Alvarez, Javier
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (E1) : E40 - E47
  • [37] Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
    Flinn, Ian W.
    Gribben, John G.
    Dyer, Martin J. S.
    Wierda, William
    Maris, Michael B.
    Furman, Richard R.
    Hillmen, Peter
    Rogers, Kerry A.
    Iyer, Swaminathan Padmanabhan
    Quillet-Mary, Anne
    Ysebaert, Loic
    Walter, Harriet S.
    Verdugo, Maria
    Klein, Christian
    Huang, Huang
    Jiang, Yanwen
    Lozanski, Gerard
    Pignataro, Daniela Soriano
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kipps, Thomas J.
    BLOOD, 2019, 133 (26) : 2765 - 2775
  • [38] BUDGET IMPACT ANALYSIS OF LURASIDONE IN THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH SCHIZOPHRENIA IN SPAIN
    Lores, M.
    Carcedo, D.
    Gabarda, I
    Sabaniego, J.
    VALUE IN HEALTH, 2022, 25 (12) : S133 - S134
  • [39] Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
    De Bellis, Eleonora
    Imbergamo, Silvia
    Candoni, Anna
    Lico, Albana
    Tanasi, Ilaria
    Mauro, Endri
    Mosna, Federico
    Leoncin, Matteo
    Stulle, Manuela
    Griguolo, Davide
    Pravato, Stefano
    Trentin, Livio
    Lazzarotto, Davide
    Di Bona, Eros
    Bassan, Renato
    Lucchini, Elisa
    Poiani, Monica
    Palmieri, Clara
    Zaja, Francesco
    LEUKEMIA RESEARCH, 2022, 114
  • [40] U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
    Lee, Hyon-Zu
    Miller, Barry W.
    Kwitkowski, Virginia E.
    Ricci, Stacey
    DelValle, Pedro
    Saber, Haleh
    Grillo, Joseph
    Bullock, Julie
    Florian, Jeffry
    Mehrotra, Nitin
    Ko, Chia-Wen
    Nie, Lei
    Shapiro, Marjorie
    Tolnay, Mate
    Kane, Robert C.
    Kaminskas, Edvardas
    Justice, Robert
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (15) : 3902 - 3907
12345